Key result
Enzyme replacement therapy over 3 years reduced left ventricular mass and improved exercise capacity only in Fabry patients without baseline myocardial fibrosis.
Why the study?
Does enzyme replacement therapy with recombinant alpha-galactosidase A improve myocardial morphology, function, and exercise capacity in patients with Fabry cardiomyopathy over long-term follow-up?
Cohort (n=32)
Does enzyme replacement therapy with recombinant alpha-galactosidase A improve myocardial morphology, function, and exercise capacity in patients with Fabry cardiomyopathy over long-term follow-up?
Enzyme replacement therapy in Fabry cardiomyopathy improves myocardial morphology, function, and exercise capacity only if initiated before the development of myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
May support early enzyme replacement in nonfibrotic Fabry cardiomyopathy; leaves open need for randomized confirmation.
BACKGROUND: Enzyme replacement therapy with recombinant alpha-galactosidase A reduces left ventricular hypertrophy and improves regional myocardial function in patients with Fabry disease during short-term treatment. Whether enzyme replacement therapy is effective in all stages of Fabry cardiomyopathy during long-term follow-up is unknown. METHODS AND RESULTS: We studied 32 Fabry patients over a period of 3 years regarding disease progression and clinical outcome under enzyme replacement therapy. Regional myocardial fibrosis was assessed by magnetic resonance imaging late-enhancement technique. Echocardiographic myocardial mass was calculated with the Devereux formula, and myocardial function was quantified by ultrasonic strain-rate imaging. In addition, exercise capacity was measured by bicycle stress test. All measurements were repeated at yearly intervals. At baseline, 9 patients demonstrated at least 2 fibrotic left ventricular segments (severe myocardial fibrosis), 11 had 1 left ventricular segment affected (mild fibrosis), and 12 were without fibrosis. In patients without fibrosis, enzyme replacement therapy resulted in a significant reduction in left ventricular mass (238+/-42 g at baseline, 202+/-46 g at 3 years; P for trend <0.001), an improvement in myocardial function (systolic radial strain rate, 2.3+/-0.4 and 2.9+/-0.6 seconds(-1), respectively; P for trend=0.045), and a higher exercise capacity obtained by bicycle stress exercise (106+/-14 and 122+/-26 W, respectively; P for trend=0.014). In contrast, patients with mild or severe fibrosis showed a minor reduction in left ventricular hypertrophy and no improvement in myocardial function or exercise capacity. CONCLUSIONS: These data suggest that treatment of Fabry cardiomyopathy with recombinant alpha-galactosidase A should best be started before myocardial fibrosis has developed to achieve long-term improvement in myocardial morphology and function and exercise capacity.
No takes yet. Share an insight, caveat, or question.
Weidemann et al. (2009) conducted a cohort in Fabry cardiomyopathy (n=32). Enzyme replacement therapy with recombinant alpha-galactosidase A was evaluated on Disease progression and clinical outcome (left ventricular mass, myocardial function, exercise capacity). Enzyme replacement therapy over 3 years reduced left ventricular mass and improved exercise capacity only in Fabry patients without baseline myocardial fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: